Today reports 2cureX interim data from its first clinical study with IndiTreat – Individual Treatment Design – a patented functional test to choose the right drug for the right patient.
IndiTreat works by producing thousands of 3D microtumors with similar functionality to the patient's actual tumor through tumor biopsy. All available treatments are tested on these microtumors and based on how the microtumors respond to the tested treatments, IndiTreat selects the most suitable treatment for each patient.
IndiTreat has achieved both primary and secondary study objectives
The company's first clinical validation study, supported by EUR 3 million from Horizon 2020, includes patients with advanced metastatic colorectal cancer whose disease continues to progress after two cycles of standard therapies. An interim analysis shows that both the primary and secondary endpoints have been met, with five out of eight patients experiencing progression-free survival (PFS) eight weeks after initiating therapy selected using IndiTreat.
In mid-2018, 2cureX announced that the ongoing clinical trial had met a secondary technical endpoint by successfully preparing 3D microtumors from needle biopsies of liver metastasis in 71 percent of cases. With today's reported results, the study's primary endpoint has also been achieved.
Makes a wider range of treatments available
Among the drugs included in the study are of course the standard treatments designated according to treatment guidelines. Due to widespread resistance to these treatments in the patient group, 2cureX and Vejle University Hospital, where the study's Principal Investigator Lars Henrik Jensen is based on also including off-label drugs, i.e. drugs that are approved for treatment in other cancer indications but that have not been designated as standard treatment in colorectal cancer.
This makes more treatment options available to patients who have shown signs of tumor resistance. Read about the issues surrounding tumor resistance here.
Being evaluated in several cancer indications
In a press release, 2cureX emphasizes that existing data has shown that it is possible to implement personalized treatment using a functional test like IndiTreat. In a longer perspective, the company is also interested in using IndiTreat in earlier stages of colorectal cancer. In addition, the test is currently undergoing clinical validation studies in both ovarian and pancreatic cancer.
The market has reacted positively to the announcement and at the time of writing the stock is up +10,5 percent for the day.
BioStock has sought the company's CEO, Ole Thastrup, who is currently in the USA. We will return with his comments on his study progress shortly.
The video explains more about how IndiTreat works:
The content of Biostock's news and analysis is independent, but Biostock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding. [et_bloom_inline optin_id=”optin_4″]